Ernexa Therapeutics Inc.
ERNA
$0.207
-$0.001-0.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -44.54M | -44.93M | -23.92M | -22.90M | -21.67M |
| Total Depreciation and Amortization | 1.64M | 2.05M | 2.12M | 1.60M | 1.12M |
| Total Amortization of Deferred Charges | 5.26M | 2.40M | 1.22M | 748.00K | 303.00K |
| Total Other Non-Cash Items | 23.78M | 23.61M | 1.96M | 2.10M | 1.95M |
| Change in Net Operating Assets | -1.98M | -81.00K | 2.13M | 343.00K | -2.12M |
| Cash from Operations | -15.84M | -16.95M | -16.49M | -18.11M | -20.41M |
| Capital Expenditure | -369.00K | -388.00K | -369.00K | -120.00K | -19.00K |
| Sale of Property, Plant, and Equipment | 4.00K | 4.00K | 4.00K | 4.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -365.00K | -384.00K | -365.00K | -116.00K | -19.00K |
| Total Debt Issued | 5.29M | 14.58M | 19.41M | 19.41M | 18.00M |
| Total Debt Repaid | -- | -1.50M | -1.50M | -1.50M | -1.50M |
| Issuance of Common Stock | 1.14M | 0.00 | 0.00 | 320.00K | 320.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -8.00K | -16.00K | -16.00K | -16.00K | -16.00K |
| Other Financing Activities | -169.00K | -110.00K | -285.00K | -271.00K | -251.00K |
| Cash from Financing | 6.26M | 12.95M | 17.61M | 17.94M | 16.56M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.94M | -4.38M | 749.00K | -281.00K | -3.87M |